Nanopore-based metagenomic sequencing for the rapid and precise detection of pathogens among immunocompromised cancer patients with suspected infections

Qingmei Deng, Yongqing Cao, Xiaofeng Wan, Bin Wang, Aimin Sun, Huanzhong Wang, Yunfei Wang, Hongzhi Wang, Hongcang GuFrontiers in Cellular and Infection Microbiology 2022 · DOI

TL;DR

This study demonstrates that nanopore amplicon sequencing is a rapid and highly sensitive method for detecting pathogens in immunocompromised cancer patients, significantly outperforming traditional culture methods. This advancement promises to improve patient outcomes by enabling earlier and more precise diagnosis and treatment of infections.

What Problem Does This Paper Address?

Cancer patients, particularly those with compromised immune systems due to treatments like chemotherapy and radiotherapy, are highly susceptible to infections. These infections can be a major cause of mortality and significantly worsen patient prognosis. Prompt and accurate diagnosis of the causative pathogen is crucial for effective treatment with appropriate anti-infectives. However, conventional culture-based methods for pathogen detection have significant limitations, including long turnaround times (days) and insufficient sensitivity, often missing fastidious organisms or leading to delayed treatment. This creates an urgent need for faster, more accurate diagnostic tools to manage infections in this vulnerable patient population.

Methods

The researchers employed a prospective study design to compare nanopore amplicon sequencing with the conventional culture method for pathogen detection.

  • Sample Collection: Body fluid samples (sputum, blood, etc.) were collected from 56 immunocompromised cancer patients with suspected infections.
  • Conventional Culture: Standard microbiological culture techniques were used, employing various agar media and incubation conditions for bacteria and fungi. Pathogen identification was performed using automated systems.
  • Nanopore Amplicon Sequencing:
    • DNA Extraction: DNA was extracted from samples using a commercial kit.
  • PCR Amplification: A multiplex PCR approach was used to amplify bacterial 16S rDNA and fungal ITS regions in a single tube. Additionally, PCR was performed to detect key DNA viruses (EBV, HCMV).
  • Library Preparation: Purified PCR products were prepared for nanopore sequencing using a specific barcoding expansion pack and a DNA library preparation kit. Two parallel libraries were prepared per sample: one for bacteria/fungi and one for viruses.
  • Sequencing: Libraries were sequenced on an Oxford Nanopore MinION platform.
  • Bioinformatic Analysis: Raw sequencing reads were processed using the EPI2ME platform (WIMP workflow). Reads were filtered for length, human DNA was removed, and remaining reads were aligned to pathogen databases for identification. Pathogens were classified based on coverage and identity scores.
  • Validation: For a subset of clinically significant pathogens, validation was performed using RT-qPCR or Sanger sequencing.
  • Limit of Detection (LoD): The LoD was evaluated by spiking known concentrations of Escherichia coli and Candida albicans into negative sputum samples.
  • Statistical Analysis: Standard statistical methods were used to compare the performance of the two methods, including t-tests, Mann-Whitney U tests, and Fisher's exact tests.

Datasets

The study utilized clinical body fluid samples from 56 immunocompromised cancer patients. No specific public datasets were used for training or evaluation; the study generated its own data from patient samples.

Key Insights and Ideas

  • Nanopore's Superiority: The study strongly suggests that nanopore amplicon sequencing is a significant leap forward compared to traditional culture methods for this patient group.
  • Catching the Missed: A critical insight is nanopore sequencing's ability to detect pathogens in a substantial portion (71.0%) of samples that were negative by culture. This highlights the pervasive issue of false negatives in conventional diagnostics.
  • Beyond the Usual Suspects: The method effectively identified fastidious pathogens and polymicrobial infections, which are often challenging for culture-based approaches.
  • Speed Matters: The dramatic reduction in turnaround time (17.5 hours vs. 3-5 days) is a game-changer for clinical decision-making, allowing for much faster initiation of targeted therapy.
  • Broad Applicability: The technique showed promise across different sample types, including blood, though its performance in blood samples was less impressive than in non-blood samples, indicating an area for future improvement.

Key Results

  • Overall Detection Rate: Nanopore sequencing detected at least one pathogen in 83.9% (47/56) of samples, compared to 44.6% (25/56) for conventional culture.
  • Culture-Negative Samples: Of the 31 culture-negative samples, nanopore sequencing successfully identified pathogens in 22 (71.0%).
  • Sensitivity: Nanopore sequencing demonstrated significantly higher sensitivity (83.9% vs. 44.6%, P<0.001). This advantage was evident in both non-blood samples (97.7% vs. 58.1%, P<0.001) and blood samples (38.5% vs. 0%, P=0.039).
  • Pathogen Types: Nanopore sequencing identified more bacterial infections (75.0% vs. 33.9%, P<0.001), fastidious pathogens (14.3% vs. 0%, P=0.006), and co-infections (48.2% vs. 12.5%, P<0.001) compared to culture.
  • Turnaround Time: The mean turnaround time for nanopore sequencing was approximately 17.5 hours, significantly shorter than the 3-5 days for conventional culture.
  • Common Pathogens Identified: Escherichia coli, Stenotrophomonas maltophilia, and Candida albicans were among the most frequently detected pathogens.

Limitations and Future Work

The authors acknowledge several limitations:

  • Blood Sample Sensitivity: While superior to culture, nanopore sequencing's sensitivity in blood samples was lower than in non-blood samples. Deeper sequencing might improve this but at a higher cost.
  • Sample Size and Diversity: The study had a relatively small sample size, and patients represented various cancer types. Future studies with larger cohorts and more specific cancer types are needed.
  • False Negatives: While rare, false negatives in nanopore sequencing are possible and require further investigation and optimization.
  • False Positives: The study noted two instances where culture identified pathogens not detected by nanopore, suggesting potential false positives in culture or false negatives in nanopore sequencing.
  • Further Exploration: The authors suggest future work should focus on optimizing nanopore sequencing for clinical utility, exploring its role in infection surveillance, and defining the spectrum of pathogens stratified by infection site or cancer type. They also propose investigating the utility of nanopore sequencing for detecting antibiotic resistance genes.

Summary updated

Abstract

Cancer patients are at high risk of infections and infection-related mortality; thereby, prompt diagnosis and precise anti-infectives treatment are critical. This study aimed to evaluate the performance of nanopore amplicon sequencing in identifying microbial agents among immunocompromised cancer patients with suspected infections. This prospective study enlisted 56 immunocompromised cancer patients with suspected infections. Their body fluid samples such as sputum and blood were collected, and potential microbial agents were detected in parallel by nanopore amplicon sequencing and the conventional culture method. Among the 56 body fluid samples, 47 (83.9%) samples were identified to have at least one pathogen by nanopore amplicon sequencing, but only 25 (44.6%) samples exhibited a positive finding by culture. Among 31 culture-negative samples, nanopore amplicon sequencing successfully detected pathogens in 22 samples (71.0%). Nanopore amplicon sequencing showed a higher sensitivity in pathogen detection than that of the conventional culture method (83.9% vs. 44.6%, P<0.001), and this advantage both existed in blood samples (38.5% vs. 0%, P=0.039) and non-blood samples (97.7% vs. 58.1%, P<0.001). Compared with the culture method, nanopore amplicon sequencing illustrated more samples with bacterial infections (P<0.001), infections from fastidious pathogens (P=0.006), and co-infections (P<0.001). The mean turnaround time for nanopore amplicon sequencing was about 17.5 hours, which was shorter than that of the conventional culture assay. This study suggested nanopore amplicon sequencing as a rapid and precise method for detecting pathogens among immunocompromised cancer patients with suspected infections. The novel and high-sensitive method will improve the outcomes of immunocompromised cancer patients by facilitating the prompt diagnosis of infections and precise anti-infectives treatment.
BibTeX
@inproceedings{deng2022nanopore,
  author = {Qingmei Deng and Yongqing Cao and Xiaofeng Wan and Bin Wang and Aimin Sun and Huanzhong Wang and Yunfei Wang and Hongzhi Wang and Hongcang Gu and Hongzhi Wang and Hongcang Gu},
  title = {{Nanopore-based metagenomic sequencing for the rapid and precise detection of pathogens among immunocompromised cancer patients with suspected infections}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2022},
  doi = {10.3389/fcimb.2022.943859},
}
Figure